First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Revolution Medicines: the story is balanced — Phase 1/2 clinical trial data readouts for RMC-6236 and RMC-6291 showing objective response rates (ORR)…
★ Analysts see FY2027 revenue reaching $804M — +681% growth in a single year.
What Moves the Stock
1Phase 1/2 clinical trial data readouts for RMC-6236 and RMC-6291 showing objective response rates (ORR), duration of response (DoR), and progression-free survival (PFS) versus existing KRAS inhibitors
2FDA regulatory milestones including IND clearances for combination trials, breakthrough therapy designations, or accelerated approval pathways
3Strategic partnership announcements or licensing deals with major pharmaceutical companies for ex-US rights or combination development
4Competitive developments from Amgen, Mirati, Eli Lilly, or other RAS inhibitor programs affecting market positioning
5Cash runway updates and equity financing announcements impacting dilution expectations
6No current commercial revenue - pre-revenue clinical-stage company
7Potential future collaboration/licensing revenue from pharmaceutical partnerships
growth - Pure speculation on clinical trial success and RAS inhibitor platform validation.
High sensitivity through multiple channels: (1) Rising rates compress biotech valuation multiples as future cash flows are discounted more…
Watch on earnings: Phase 1/2 objective response rates (ORR) for RMC-6236 in KRAS G12C patients - must exceed 40-50% to compete with Lumakras/Krazati, Duration of response (DoR) and progression-free survival (PFS) data demonstrating durability versus existing KRAS inhibitors, Quarterly cash burn rate and remaining cash runway - critical for anticipating dilutive financing events.
One Sentence Summary:
Revolution Medicines: the story is balanced — phase 1/2 clinical trial data readouts for rmc-6236 and rmc-6291 showing objective response rates (orr), duration of response (dor).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.